 |
BioWorld-International-2011-02-23
Philogen IPO a No-Go After Bayer Nixes Antibody Deal
Philogen IPO a No-Go After Bayer Nixes Antibody Deal
LONDON – Philogen SpA pulled its initial public offering on the Milan Stock Exchange after partner Bayer Schering Pharma AG peremptorily terminated a licensing and collaboration deal between the two for the development of vascular-targeting antibodies in the treatment of cancer. (BioWorld International)
Actelion Issues First Dividend Hoping to Stall a Push to Sell
LONDON – Actelion Ltd. announced its first-ever dividend to shareholders as it published annual results for 2010 in a move that is intended to stop other investors lining up behind Elliott Advisors, the U.S. hedge fund that is exerting pressure for a sale of the company.
'Intrinsic Disorder,' Though Not Chaos, Reigns in Cells
WASHINGTON – "The textbook view on proteins is that they are globular. They are globular, they are well-folded and their function relates entirely to their form," summarized Peter Wright of the Scripps Institute.